Newsletter

Progenics Pharmaceuticals Reports Top Line Phase 3 Clinical Trial Results

On September 13, Progenics Pharmaceutical, Inc. (PGNX) reported Phase 3 clinical trial results from its study of 1404, the company’s prostate specific membrane antigen (PSMA). It is a targeted small molecule SPECT/CT imaging agent designed to visualize prostate cancer. The results met one of the co-primary endpoints of identifying patients without clinically significant prostate cancer. […]

0Comments

ProQR Therapeutics Reports Positive Clinical Trial Results Treating LCA10

On September 5, ProQR Therapeutics, N.V. (PRQR) announced positive results from its Phase 1/2 trial of QR-110 in patients with Leber’s congenital amaurosis 10 (LCA 10) due to a mutation in the CEP290 gene. LCA10 usually leads to childhood blindness and currently has no available treatment options. Patients in the trial had rapid and sustained […]

0Comments

August 2018 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: August Scorecard Number of Signals 39 Percent Correct – Prev Close to 5-day Peak 97% Avg Increase – Next open to 5-day Peak 7% Other stats: Number of signals over $10/share 25 Number […]

0Comments

INSYS Therapeutics Receives FDA Fast Track Designation for Epinephrine Nasal Spray

INSYS Therapeutics, Inc. (INSY) announced on August 30 that the company received a Fast Track from the FDA for the company’s epinephrine nasal spray. The spray is an investigational drug for the treatment of anaphylaxis, a life-threatening allergic reaction requiring urgent treatment. INSYS is a leader in the development, manufacture, and commercialization of pharmaceutical cannabinoids […]

0Comments

July 2018 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: July Scorecard Number of Signals 21 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 15% Other stats: Number of signals over $10/share 14 Number […]

0Comments

Regeneron Pharmacueticals and Teva Pharmaceutical Report Positive Topline Phase 3 Clinical Trial Results of Fasinumab

On August 16, Regeneron Pharmaceuticals, Inc. (REGN) and Teva Pharmaceutical Industries Ltd. (TEVA) announced positive topline results from a Phase 3 clinical trial of Fasinumbab in patients with chronic pain from osteoarthritis of the knee or hip. After 16 weeks, the study met both co-primary endpoints as well as all key secondary endpoints. Patients treated […]

0Comments

Strongbridge Biopharma Reports Positive Results in Phase 3 SONICS Study of RECORLEV

On August 8, Strongbridge Biopharma plc (SBBP) announced top-line results from its Phase 3 SONICS study evaluating RECORLEVTM(levoketoconazole) for the treatment of endogenous Cushing’s syndrome. The open-label, single-arm SONICS study produced statistically significant results of its pre-specified primary endpoint. At six months, 30% of patients demonstrated a normalization rate of Urinary Free Cortisol. Rocket Tickers […]

0Comments

Reata Pharmaceuticals Reports Positive Phase 2 Results From Two Clinical Trials

On July 23, Reata Pharmaceuticals, Inc. (RETA) announced results from two Phase 2 clinical trials of bardoxolone in patients with chronic kidney disease. The one-year results for the Phase 2 portion of CARDINAL, a study of bardoxolone in patients with chronic kidney disease due to Alport syndrome, found that patients had no drug-related negative side […]

0Comments

Aclaris Therapeautics Reports Positive Phase 2 Clinical Trial Results

On June 28, Aclaris Therapeutics (ACRS) reported positive interim results from its Phase 2 clinical trial of AA-202 Topical. The drug is an investigational topical to treat two of the more severe variants of Alopecia Areata. Patients did not experience any treatment-related serious adverse events, and results for the full patient sample will be reported […]

0Comments

IsoRay Receives FDA 510(k) Clearance for GammaTileTM Therapy

On July 9, IsoRay, Inc. (ISR) and GT Medical Technologies, Inc. announced they received FDA 510(k) regulatory clearance for their brachytherapy technology, known as GammaTileTMTherapy. The therapy incorporates proprietary Cesium-131 seeds within customizable collagen-based carriers to treat recurrent brain tumors. The two companies previously executed a ten-year collaborative development agreement.   Rocket Tickers detected the […]

0Comments